Last reviewed · How we verify
NCT05167630
Prognosis Factors in Patients With Primary Central Nervous System Lymphoma
trial testing prognostic marker in PCNSL in 40 participants. Status unknown.
15 December 2021
Quick facts
| Lead sponsor | Zhengzhou University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 40 |
| Start date | 1 September 2013 |
| Primary completion | 15 December 2021 |
| Estimated completion | 15 December 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- prognostic marker
Conditions studied
- PCNSL — all drugs for PCNSL →
- Survival Analysis — all drugs for Survival Analysis →
Sponsor
Zhengzhou University
Who can join
Eligibility, any sex, with PCNSL or Survival Analysis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Primary central nervous system lymphoma (PCNSL) is a rare extranodal non-hodgkin's lymphoma confined to the central nervous system. It accounts for about 4% of all intracranial tumors and 4% to 6% of all non-Hodgkin's lymphomas . Among them, the most common type is diffuse large B cell lymphoma (DLBCL), accounting for about 95% of all cases. High dose methotrexate (HD-MTX) based chemotherapy can improve the prognosis of patients, but only 30% to 40% of patients can achieve sustained remission, and the overall prognosis is very poor\[4, 6\]. Currently, the International Extranodal Lymphoma Study Group (IESLG) prognostic scoring system and the Memorial Sloan Kettering Cancer Center (MSKCC) prognostic index are widely used to evaluate the prognosis in patients with PCNSL. However, IESLG model has some limitations such as the relatively small number of patients and short follow-up period. MSKCC model may have an inherent selection bias because retrospective data were collected from a single large institution. Therefore, there is a urgent need to identify novel indicators for prognosis evaluation and risk stratification in PCNSL patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05167630
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for PCNSL
Currently open trials in the same condition.
- NCT07350850 — A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Re · Phase 2 · recruiting
- NCT06554561 — A Study of Pomadomide in Combination With Rituximab and Methotrexate for Newly-diagnosed Primary Central Nervous System · Phase 1, PHASE2 · recruiting
- NCT05782374 — Real World Data on Ibrutinib Use in PCNSL Rel/Ref · active not recruiting
Other Zhengzhou University trials
Trials by the same sponsor.
- NCT07299331 — Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma · NA · not yet recruiting
- NCT07264894 — ZSDT for the Treatment of R/R Mantle Cell Lymphoma After BTK Inhibitor Failure: a Multi-center Prospective Clinical Tria · Phase 4 · not yet recruiting
- NCT07198464 — Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilima · NA · not yet recruiting
- NCT07117305 — CD7 CAR-T Combined With Autologous Hematopoietic Stem Cell Transplantation · Phase 1, PHASE2 · not yet recruiting
- NCT06609304 — Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05167630 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhengzhou University
- Last refreshed: 22 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05167630.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing